Corvus Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| · · Year Ended December 31, | |||||||||
| · 2023 · 2022 · 2021 | |||||||||
| Operating expenses: · · · · | |||||||||
| Research and development | | $16,526 | | $24,468 | | $29,115 | |||
| General and administrative | | 6,881 | | 8,097 | | 9,515 | |||
| Total operating expenses | | 23,407 | | 32,565 | | 38,630 | |||
| Loss from operations | | (23,407) | | (32,565) | | (38,630) | |||
| Interest income and other expense, net | | 1,584 | | 654 | | (15) | |||
| Gain from sale of property and equipment | | | — | | | 22 | | | — |
| Sublease income - related party | | | 78 | | | 587 | | | 235 |
| Loss from equity method investment | | | (5,284) | | | (10,005) | | | (4,831) |
| Net loss | | $(27,029) | | $(41,307) | | $(43,241) | |||
| Net loss per share, basic and diluted | | $(0.56) | | $(0.89) | | $(1.03) | |||
| Shares used to compute net loss per share, basic and diluted | | 48,025,274 | | 46,553,511 | | 41,854,110 | |||
| Other comprehensive loss: | | | | | |||||
| Unrealized gain (loss) on marketable securities | | 66 | | (48) | | (7) | |||
| Cumulative foreign currency translation adjustment | | (470) | | (2,384) | | 1,872 | |||
| Comprehensive loss | | $(27,433) | | $(43,739) | | $(41,376) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.